What is LTRN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LTRN?

P/E (TTM) is n/a and 52-week range is $0.83 to $4.70 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LTRN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LTRN?

The company profile lists net income (TTM) near $-21M, EPS (TTM) near $-1.61 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lantern Pharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Dallas, Texas, US, 12.8M shares outstanding, ISIN US51654W1018 when available from company profile and filing metadata.

Lantern Pharma Inc

$LTRN

Health Care · Biotechnology

IR Run Scenarios

$0.81

-2.08%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2020-06-11. The firm is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. The company is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. The company has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. The company is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Employees

Website

www.lanternpharma.com/

IPO

2020-06-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)